Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

ADC play Ambrx files for IPO

May 3, 2014 1:30 AM UTC

Ambrx Inc. (La Jolla, Calif.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Stifel; Wells Fargo Securities; Canaccord; Needham; and Roth Capital Partners. Ambrx is developing a pipeline of antibody-drug conjugates by engineering non-native amino acids into mAbs via site-specific conjugation. The company is also developing bispecific and multi-specific drug conjugates and long-acting proteins. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article